HHHiroyuki Hounoki

Hiroyuki Hounoki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hiroyuki Hounoki has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Association between tazobactam–piperacillin exposure and the subsequent emergence in gram-negative rods: Findings from a single-institution cohort study

    by Ezaki Masayoshi, Kato Noriko, Nagaoka Kentaro, Murai Yushi, Sugie Kazushige, Kamihara Yusuke, Hounoki Hiroyuki, Watanabe Toru, Kawagishi Toshiomi, Yonemoto Naohiro, et al.


  • Low-dose, not low-risk: potential adrenal suppression identified by a risk-based approach to ACTH testing

    by Ryoko Asano, Satoshi Yamaguchi, Koichiro Shinoda, Hiroyuki Hounoki, Toshiki Kido, Masatoshi Kawataka, Naonori Sugishita, Miho Yamazaki, Ikuma Okada, Aoi Kobiyama, et al.

    Objectives This study aimed to investigate the frequency and associated factors of impaired adrenal response on Synacthen test in patients with rheumatic diseases undergoing low-dose maintenance GC therapy. Methods This single-center, retrospective, observational study included 48 patients with autoimmune rheumatic diseases on maintenance GC therapy (prednisolone ≤ 5 mg/day) who had previously received ≥ 5 mg/day for ≥ 3 months and underwent adrenal function testing between January 2021 and May 2023. Impaired adrenal response was defined by both low baseline cortisol and inadequate response to the standard-dose (250 μg) Synacthen test in this study. Daily dose, treatment duration, cumulative dose, and history of methylprednisolone pulse therapy were evaluated. Statistical comparisons were performed using Mann–Whitney U, Fisher’s exact, and receiver operating characteristic (ROC) analyses. Results Impaired adrenal response on Synacthen test meeting the study-defined criteria was identified in 30 of 48 patients (62.5%). Compared with the normal adrenal response group, affected patients had significantly higher cumulative GC doses, lower baseline cortisol levels, and more frequent histories of methylprednisolone pulse therapy. Exploratory ROC analysis identified an optimal cumulative glucocorticoid dose cutoff of 10,371.5 mg associated with impaired adrenal response on Synacthen test (prednisolone equivalent). Conclusions Impaired adrenal response on Synacthen test was frequently observed among patients selected for adrenal function testing during maintenance GC therapy at ≤ 5 mg/day. Higher cumulative GC exposure and prior pulse therapy were associated with impaired adrenal response on Synacthen test, suggesting that a targeted, risk-based approach to adrenal evaluation may be useful even during low-dose treatment. Key Points • Impaired adrenal response on Synacthen test was detected in 62.5% of patients selected for adrenal function testing during maintenance glucocorticoid therapy at ≤ 5 mg/day. • A cumulative glucocorticoid dose ≥ 10,371.5 mg was associated with impaired adrenal response on Synacthen test. • Exploratory ROC analysis identified basal cortisol ≤ 6.1 μg/dL and daily glucocorticoid dose ≥ 3.5 mg as potential thresholds associated with impaired adrenal response on Synacthen test. • Adrenal suppression may occur even in clinically stable patients receiving low-dose therapy.

  • Open Access

    A Case Report of Anti-TIF1-γAntibody-Positive Dermatomyositis Concomitant with Small Cell Neuroendocrine Carcinoma of the Urinary Bladder

    by Hiroyuki Hounoki, Takafumi Onose, Miho Yamazaki, Ryoko Asano, Satoshi Yamaguchi, Koichiro Shinoda, Kazuyuki Tobe, Akira Noguchi, Kenichi Hirabayashi

    Small cell neuroendocrine carcinoma is rare among urinary bladder cancer types, and to date, there are no case reports of concurrent antitranscriptional intermediary factor 1-γantibody-positive dermatomyositis. We describe the case of a 69-year-old Japanese man who presented with elevated creatine kinase levels and haematuria on medical examination. Approximately one month later, he developed dysphagia. Laryngoscopy confirmed laryngeal dysfunction. He also presented with muscle weakness and a skin rash. Magnetic resonance imaging of the upper extremities suggested bilateral brachial muscle myositis. He was diagnosed as having dermatomyositis and was later found to be positive for antitranscriptional intermediary factor 1-γ antibody. Computed tomography revealed an intravesical space-occupying lesion and right iliac lymphadenopathy, suggesting urinary bladder cancer. The patient was admitted to our hospital for treatment. Urinary bladder biopsy confirmed small cell neuroendocrine carcinoma because tumour cells were positive for synaptophysin, CD56, and chromogranin A. Thus, the patient was diagnosed as having an antitranscriptional intermediary factor 1-γantibody-positive dermatomyositis concomitant with urinary bladder small cell neuroendocrine carcinoma. The patient was treated with glucocorticoid and intravenous immune globulin therapy for dermatomyositis. Radiotherapy was selected for the carcinoma. Although muscle weakness and skin symptoms improved with treatment, dysphagia persisted. Furthermore, expression of the transcriptional intermediary factor 1-γ protein in tumour cells was also confirmed by immunohistochemistry, but the significance is unknown. It should be noted that antitranscriptional intermediary factor 1-γantibody-positive dermatomyositis can occur concomitantly with such a rare malignancy.


  • Open Access

    Inhibition of Tumor Progression Locus 2 Protein Kinase Suppresses Receptor Activator of Nuclear Factor-.KAPPA.B Ligand-Induced Osteoclastogenesis through Down-Regulation of the c-Fos and Nuclear Factor of Activated T Cells c1 Genes

    by Kazuya Hirata, Hirofumi Taki, Kouichiro Shinoda, Hiroyuki Hounoki, Tatsuro Miyahara, Kazuyuki Tobe, Hirofumi Ogawa, Hisashi Mori, Eiji Sugiyama

    Whether tumor progression locus 2 (Tpl2)/cancer Osaka thyroid (Cot) protein kinase participates in osteoclastogenesis from receptor activator of nuclear factor-kappaB ligand (RANKL)-stimulated monocytes/macrophages remains elusive. To clarify this, a selective and potent inhibitor of Tpl2, 1,7-naphtyridine-3-carbonitrile, was used. When RAW264.7 cells were stimulated with RANKL, Tpl2 was found to be activated. Under this condition, the Tpl2 inhibitor suppressed osteoclastogenesis in a dose-dependent manner. This was due to the blockade of the phosphorylation of mitogen activated protein kinase/ERK kinase (MEK) and extracellular signal-regulated kinase (ERK), but not c-Jun N-terminal kinase (JNK) or p38, concomitant with the down-regulation of the c-Fos and nuclear factor of activated T cells (NFAT)c1 genes. A long period of RANKL-stimulated cell exposure to the inhibitor suppressed osteoclastogenesis as assessed by tartrate-resistant acid phosphatase (TRAP) staining and pit formation on dentin slices. Almost identical results were obtained with macrophage colony-stimulating factor (M-CSF) and RANKL-stimulated bone marrow cells. These findings suggest the possibility that Tpl2 plays a pivotal role in osteoclastogenesis and thus that its inhibitor is useful for investigating the differentiation of monocytes/macrophages to osteoclasts after treatment with RANKL or other stimuli.